Experimental therapy of chronic kidney ischemia using drug basic fibroblast growth factor

S.  Bazalytska; G.  Nikulina; V.  Kordium; I.  Dubey; S.  Vozianov; A.  Romanenko; Ia.  Pokholenko; S.  Nikitaev; I.  Serbina; L.  Mygal; O.  Vozianov

doi:10.31450/ukrjnd.3(75).2022.06

S. Bazalytska SI "Academician O.F.Vozianov Institute of Urology" NAMS of Ukraine https://orcid.org/0000-0003-0191-6160
G. Nikulina SI "Academician O.F.Vozianov Institute of Urology" NAMS of Ukraine
V. Kordium Institute of Molecular Biology and Genetics NAS of Ukraine
I. Dubey Institute of Molecular Biology and Genetics NAS of Ukraine
S. Vozianov SI "Academician O.F.Vozianov Institute of Urology" NAMS of Ukraine
A. Romanenko SI "Academician O.F.Vozianov Institute of Urology" NAMS of Ukraine
Ia. Pokholenko Institute of Molecular Biology and Genetics NAS of Ukraine
S. Nikitaev SI "Academician O.F.Vozianov Institute of Urology" NAMS of Ukraine
I. Serbina SI "Academician O.F.Vozianov Institute of Urology" NAMS of Ukraine
L. Mygal SI "Academician O.F.Vozianov Institute of Urology" NAMS of Ukraine
O. Vozianov SI "Academician O.F.Vozianov Institute of Urology" NAMS of Ukraine

DOI: https://doi.org/10.31450/ukrjnd.3(75).2022.06

Keywords: chronic kidney ischemia, basic fibroblast growth factor, vascular coefficient, interstitial coefficient, enzymes.

Abstract

Abstract. The aim of the work was to experimentally study the effect of the created injectable drug basic fibroblast growth factor (bFGF) with the controlled release on morphological changes and indicators of renospecific enzymes in the ischemic kidney (experiment on rabbits).

Methods. Studies on the release dynamics of the created bFGF drug were performed in vitro and the study of the induction of bFGF angiogenesis in the model of the chick chorioallantoic membrane of the chicken was performed. The experimental model was performed in 25 rabbits: in 10 rabbits we studied the effect of 1-8 months of "pure ischemia" of the kidney without injection of the drug (control); in 12 rabbits 1 month after the creation of the model of ischemia in the renal parenchyma was injected the prolonged-acting drug bFGF, deposited on our polymeric carrier at a dose of 5 μg (experiment). The reference group consisted of 3 intact rabbits. Histological examinations of renal tissue and morphometric examinations with the determination of vascular coefficient (VC) and interstitial coefficient (IC) were performed. Enzymological indicators of enzyme activity in the homogenate of the renal parenchyma were determined by biochemical methods; statistical analysis was performed.

Results. Using chick chorioallantoic membrane as a model it was preliminarily demonstrated that developed injectable prolonged-acting drug bFGF deposited on a polymeric carrier based on cross-linked modified heparin, effectively enhances neoangiogenesis.

The results of morphological and morphometric studies with the determination of vascular and interstitial coefficients showed, that the injection of the prolonged-acting drug bFGF in all cases was accompanied by an increased blood supply in the kidneys and neoangiogenesis, which reduced the effects of ischemia.

Injection of bFGF at a dose of 5 μg in the model of chronic segmental renal ischemia for 3-4 months completely prevented the development of initial sclerotic and atrophic changes, that developed in the kidney during this period under the influence of chronic ischemia without bFGF. Injection of prolonged-acting bFGF at a dose of 5 μg in the model of chronic segmental renal ischemia for 5-8 months prevented expressed sclerotic and atrophic changes, that developed under the influence of chronic ischemia during this period without the use of bFGF.

As a result of biochemical studies, the activation and normalization of indicators of renospecific tubular enzymes in the ischemic kidney under the action of the created experimental drug bFGF were determined.

Conclusions. Therapy of ischemic changes in the kidney with the developed injectable long-acting drug bFGF at a dose of 5 µg in the experimental model of chronic ischemia protects the organ from hypoxic damage, has a positive effect on the structural and functional state and metabolism of the kidney, and prevents the development of nephrosclerosis.

Downloads

Download data is not yet available.

References

Chade AR, Stewart N. Angiogenic cytokines in renovascular disease: do they have potential for therapeutic use? J. Am. Soc. Hypertens. 2013;7(2):180–90. doi: 10.1016/j.jash.2013.01.004.

Iwakura А, Fujita M, Kataoka K, Tambara K, Sakakibara Y, Komeda M, et al. Intramyocardial sustained delivery of basic fibroblast growth factor improves angiogenesis and ventricular function in a rat infarct model. Heart Vessels. 2003;18(2): 93-9. doi: 10.1007/s10380-002-0686-5.

Kawasuji M, Naqamine H, Ikeda M, Sakakjbara N, Takemura H, Fujis S, et al. Therapeutic angiogenesis with intramyocardial administration of basic fibroblast growth factor. Ann. Thorac. Surg. 2000;69(4):1155-61. doi: 10.1016/S0003-4975(99)01557-X.

Kumagai M, Minakata K, Masumoto H, Yamamoto M, Yonezawa A, Ikeda T, et al. A therapeutic angiogenesis of sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogel sheets in a canine chronic myocardial infarction model. Heart Vessels. 2018;33(10):1251-7. doi: 10.1007/s00380-018-1185-6.

Villanueva S, Cespedes C, Gonzalez AA, Vio CP. bFGF induces an earlier expression of nephrogenic proteins after ischemic acute renal failure. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2006;291:1677-87. doi: 10.1152/ajpregu.00023.2006.

Villanueva S, Cespedes C, Gonzalez AA, Roessler E, Vio CP. Inhibition of bFGF-receptor type 2 increases kidney damage and suppresses nephrogenic protein expression after ischemic acute renal failure. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008; 294(3):819-28. doi: 10.1152/ajpregu.00273.2007.

Vargason, AM, Anselmo AC, Mitragotri S. The evolution of commercial drug delivery technologies. Nat.Biomed.Eng. 2021;5:951-67. doi: 10.1038/s41551-021-00698-w.

Jin H, Quesada C, Aliabouzar M, Kripfgans OD, Franceschi RT, Liu J, et al. Release of basic fibroblast growth factor from acoustically-responsive scaffolds promotes therapeutic angiogenesis in the hind limb ischemia model. J Control Release. 2021 Oct 10;338:773–83. doi: 10.1016/j.jconrel.2021.09.013.

Pokholenko IaO, Chetyrkina MD, Dubey, LV, Dubey IYa, Moshynets OV, Sheludko EV, et al. Development and characterization of porous functionalized collagen scaffolds for delivery of FGF-2. Biopolym. Cell. 2014; 30:216-22. doi: 10.7124/bc.000899.

Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: A laboratory manual. 2 ed. NY: Cold Spring Harbor Laboratory Press; 1989, 1659 p.

Wilting J, Christ B, Bokeloh M. A modified chorioallantoic membrane (CAM) assay for qualitative and quantitative study of growth factors. Anat. Embryol. (Berl). 1991;183(3):259-71. doi: 10.1007/BF00192214.

Vozianov OF, Pyrohov VO, Zubko VI, Nikitaiev SV, Romanenko AM, Bazalytska SV, ta in. vynakhidnyky; DU "In-t urolohii NAMN Ukrainy", patentovlasnyk. Sposib modeliuvannia ishemii nyrky. Patent Ukrainy na korysnu model. № 65480. 2011 Hrud. 12. [In Ukrainian].

Pyrohov VO, Myhal LYa, Nikulina HH, Nikitaiev SV, Serbina IYe, vynakhidnyky; DU "In-t urolohii NAMN Ukrainy", patentovlasnyk. Sposib vyznachennia aktyvnosti N-atsetyl-β-D-hliukozaminidazy v parenkhimi nyrky. Patent Ukrainy na korysnu model № 83116, 2014 Serp. 27. [In Ukrainian].

Lazarous DF, Shou M, Stiber JA, Dadhania DM, Thirumurti V, et al. Pharmacodynamics of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution. Cardiovasc. Res. 1997;36(1):78-85. doi: 10.1016/S0008-6363(97)00142-9.

Schumacher B, Stegmann T, Pecher P. The stimulation of neoangiogenesis in the ischemic human heart by the growth factor FGF: first clinical results. J. Cardiovasc. Surg. (Torino) 1998; 39 (6): 783-9. PMID: 9972900.

Vozianov OF, Kordium VA, Pyrohov VO, Romanenko AM, Zubko VI, vynakhidnyky; DU "In-t urolohii NAMN Ukrainy", In-t molekuliarnoi biolohii i henetyky NAN Ukrainy, patentovlasnyky. Zastosuvannia osnovnoho faktora rostu fibroblastiv (bFGF) yak zasobu dlia korektsii porushen krovoobihu v nyrkakh. Patent Ukrainy na korysnu model. №26456, 2007 Veres.25. [In Ukrainian].

Dong Y, Zhang Q, Wen J, Chen T, He L, Wang Yi, et al. Ischemic duration and frequency determines AKI-to CKD progression monitored by dynamic changes of tubular biomarkers in IRI mice. Front. Physiol. 2019;10:153. doi: 10.3389/fphys.2019.00153.

Pyrohov VO, Kordium VA, Zubko VI, Myhal LIa, Nikulina HH, Dubei IIa, vynakhidnyky; DU "In-t urolohii NAMN Ukrainy", In-t molekuliarnoi biolohii i henetyky NAN Ukrainy, patentovlasnyky. Sposib korektsii porushen krovoobihu v nyrkakh iz eksperymentalno zmodelovanoiu ishemiieiu. Patent Ukrainy na korysnu model №88695. 2014 Berez. 25. [In Ukrainian].

Labunets IF, Utko NA, Toporova OK, Savosko SI, Pokholenko IaO, Panteleymonova TN, Butenko GM. Melatonin and fibroblast growth factor-2 potentiate the effects of human umbilical cord multipotent mesenchymal stromal cells in mice with cuprizone-induced demyelination. Biopolym. Cell. 2021; 5(37): 369-78. doi: 10.7124/bc.000A62.

Labunets I, Utko N, Toporova O, Pokholenko Ia, Panteleymonova T, Litoshenko Z, Butenko G. The effects of combined administration of human umbilical cord-derived multipotent mesenchymal stromal cells and melatonin or fibroblast growth factor-2 to aged mice with a toxic cuprizone model of demyelination Cell and Organ Transplantology. 2021; 9(1):4-10. doi: 10.22494/cot.v9i1.116.